论文部分内容阅读
[目的]评价射频消融联合吉西他滨、顺铂经支气管动脉灌注化疗治疗中晚期非小细胞肺癌的临床疗效。[方法]26例中晚期非小细胞肺癌患者,采用吉西他滨、顺铂经支气管动脉化疗灌注化疗,于首次化疗后3周左右在CT引导下对病灶进行射频消融治疗1次,随访并记录术后3个月、半年、1年的有效率、生存率与生活质量。并与单纯采用吉西他滨、顺铂经支气管动脉灌注化疗的27例对照组患者进行有效率与生存率的比较。[结果]联合组术后3个月、半年、1年有效率/生存率分别为92.3%/100%、76.9%/96.2%、46.2%/84.6%,对照组有效率/生存率分别为85.2%/100%、63.0%/85.2%、25.9%/66.7%,联合治疗组有效率与生存率均明显高于对照组(P<0.05)。联合组生活质量高于对照组(P<0.05)。[结论]射频消融联合吉西他滨、顺铂经支气管动脉灌注化疗治疗中晚期非小细胞肺癌具有较好的临床疗效,是一种较为理想、安全有效的综合性治疗手段。
[Objective] To evaluate the clinical effect of radiofrequency ablation combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer by bronchial artery infusion chemotherapy. [Methods] Twenty-six patients with advanced non-small cell lung cancer received chemotherapy with chemotherapeutic drugs, such as gemcitabine and cisplatin. The patients were treated with CT guided radiofrequency ablation about 3 weeks after the first chemotherapy. The patients were followed up and recorded 3 months, half a year, 1 year efficiency, survival rate and quality of life. The efficacy and survival rates of 27 patients who received chemotherapy with gemcitabine and cisplatin via bronchial arterial infusion were compared. [Results] The effective rates / survival rates at 3 months, 6 months and 1 year after operation in the combined group were 92.3% / 100%, 76.9% / 96.2% and 46.2% / 84.6%, respectively, while those in the control group were 85.2 % / 100%, 63.0% / 85.2%, 25.9% / 66.7% respectively. The effective rate and survival rate of the combined treatment group were significantly higher than those of the control group (P <0.05). The quality of life in the combined group was higher than that in the control group (P <0.05). [Conclusion] Radiofrequency ablation combined with gemcitabine and cisplatin through bronchial artery infusion chemotherapy in the treatment of advanced non-small cell lung cancer has good clinical curative effect, which is an ideal, safe and effective comprehensive treatment.